Drugs / Rinzimetostat
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07723248 Comparator | Aug 2026 → Mar 2028 expected | castration-resistant prostate carcinoma | ORIC Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rinzimetostat | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07723248 ↗ |